Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Dina Battino, Torbjörn Tomson, Erminio Bonizzoni, John Craig, Emilio Perucca, Anne Sabers, Sanjeev Thomas, Silje Alvestad, Piero Perucca, Frank Vajda
IMPORTANCE: Women with epilepsy (WWE) require treatment with antiseizure medications (ASMs) during pregnancy, which may be associated with an increased risk of major congenital malformations (MCMs) in their offspring. OBJECTIVE: To investigate the prevalence of MCMs after prenatal exposure to 8 commonly used ASM monotherapies and changes in MCM prevalence over time. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, observational, longitudinal cohort study conducted from June 1999 to October 2022...
March 18, 2024: JAMA Neurology
#22
JOURNAL ARTICLE
Mark J Kelly, Eleanor Grant, Andrew G Murchison, Sophie Binks, Sudarshini Ramanathan, Sophia Michael, Adam E Handel, Lahiru Handunnetthi, Christopher E Uy, John N Soltys, Divyanshu Dubey, Gregory S Day, A Sebastian Lopez-Chiriboga, Eoin P Flanagan, Fintan Sheerin, Sarosh R Irani
IMPORTANCE: Rapid and accurate diagnosis of autoimmune encephalitis encourages prompt initiation of immunotherapy toward improved patient outcomes. However, clinical features alone may not sufficiently narrow the differential diagnosis, and awaiting autoantibody results can delay immunotherapy. OBJECTIVE: To identify simple magnetic resonance imaging (MRI) characteristics that accurately distinguish 2 common forms of autoimmune encephalitis, LGI1- and CASPR2-antibody encephalitis (LGI1/CASPR2-Ab-E), from 2 major differential diagnoses, viral encephalitis (VE) and Creutzfeldt-Jakob disease (CJD)...
March 18, 2024: JAMA Neurology
#23
JOURNAL ARTICLE
Yang Su, Minjin Wang
No abstract text is available yet for this article.
March 18, 2024: JAMA Neurology
#24
JOURNAL ARTICLE
Yaping Yan, Wei Qiu
No abstract text is available yet for this article.
March 18, 2024: JAMA Neurology
#25
JOURNAL ARTICLE
Faheem Arshad, Suvarna Alladi
No abstract text is available yet for this article.
March 18, 2024: JAMA Neurology
#26
JOURNAL ARTICLE
Marianna Cortese, Yumei Leng, Kjetil Bjornevik, Moriah Mitchell, Brian C Healy, Michael J Mina, James D Mancuso, David W Niebuhr, Kassandra L Munger, Stephen J Elledge, Alberto Ascherio
IMPORTANCE: It remains unclear why only a small proportion of individuals infected with the Epstein-Barr virus (EBV) develop multiple sclerosis (MS) and what the underlying mechanisms are. OBJECTIVE: To assess the serologic response to all EBV peptides before the first symptoms of MS occur, determine whether the disease is associated with a distinct immune response to EBV, and evaluate whether specific EBV epitopes drive this response. DESIGN, SETTING, AND PARTICIPANTS: In this prospective, nested case-control study, individuals were selected among US military personnel with serum samples stored in the US Department of Defense Serum Repository...
March 18, 2024: JAMA Neurology
#27
JOURNAL ARTICLE
Yu Guo, Qing Peng, Chen Ling
No abstract text is available yet for this article.
March 11, 2024: JAMA Neurology
#28
JOURNAL ARTICLE
Yu Kan Au, Mohammed F Kananeh, Rahul Rahangdale, Timothy Eoin Moore, Gregory A Panza, Nicolas Gaspard, Lawrence J Hirsch, Andres Fernandez, Syed Omar Shah
IMPORTANCE: Multiple continuous intravenous anesthetic drugs (CIVADs) are available for the treatment of refractory status epilepticus (RSE). There is a paucity of data comparing the different types of CIVADs used for RSE. OBJECTIVE: To systematically review and compare outcome measures associated with the initial CIVAD choice in RSE in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. EVIDENCE REVIEW: Data sources included English and non-English articles using Embase, MEDLINE, PubMed, and Web of Science (January 1994-June 2023) as well as manual search...
March 11, 2024: JAMA Neurology
#29
JOURNAL ARTICLE
Anne H Cross, Jeffrey M Gelfand, Simon Thebault, Jeffrey L Bennett, H Christian von Büdingen, Briana Cameron, Robert Carruthers, Keith Edwards, Robert Fallis, Rachel Gerstein, Paul S Giacomini, Benjamin Greenberg, David A Hafler, Carolina Ionete, Ulrike W Kaunzner, Lay Kodama, Christopher Lock, Erin E Longbrake, Bruno Musch, Gabriel Pardo, Fredrik Piehl, Martin S Weber, Steven Yuen, Tjalf Ziemssen, Gauruv Bose, Mark S Freedman, Veronica G Anania, Akshaya Ramesh, Ryan C Winger, Xiaoming Jia, Ann Herman, Christopher Harp, Amit Bar-Or
IMPORTANCE: Biomarkers distinguishing nonrelapsing progressive disease biology from relapsing biology in multiple sclerosis (MS) are lacking. Cerebrospinal fluid (CSF) is an accessible fluid that most closely reflects central nervous system biology. OBJECTIVE: To identify CSF biological measures associated with progressive MS pathobiology. DESIGN, SETTING, AND PARTICIPANTS: This cohort study assessed data from 2 prospective MS cohorts: a test cohort provided serial CSF, clinical, and imaging assessments in a multicenter study of patients with relapsing MS (RMS) or primary progressive MS (PPMS) who were initiating anti-CD20 treatment (recruitment: 2016-2018; analysis: 2020-2023)...
March 11, 2024: JAMA Neurology
#30
JOURNAL ARTICLE
Hui-Sheng Chen, Yu Cui, Xin-Hong Wang, Yu-Tong Ma, Jing Han, Ying-Jie Duan, Jiang Lu, Li-Ying Shen, Yong Liang, Wei-Zhong Wang, Hui Wang, Yong Zhao, Jin-Tao Zhang, Yu-Lin Song, Xiao-Mei He, Run-Hui Li, Ding-Bo Tao, Jing Li, Shu-Man Huang, Ni Wang, Mei Hong, Chong Meng, Wei Zhang, Duo-Lao Wang, Thanh N Nguyen
IMPORTANCE: Dual antiplatelet therapy has been demonstrated to be superior to single antiplatelet in reducing recurrent stroke among patients with transient ischemic attack or minor stroke, but robust evidence for its effect in patients with mild to moderate ischemic stroke is lacking. OBJECTIVE: To evaluate whether dual antiplatelet therapy is superior to single antiplatelet among patients with mild to moderate ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, open-label, blinded end point, randomized clinical trial conducted at 66 hospitals in China from December 20, 2016, through August 9, 2022...
March 11, 2024: JAMA Neurology
#31
JOURNAL ARTICLE
Chong Yan, Yaoxian Yue, Yuzhou Guan, Bitao Bu, Qing Ke, Ruisheng Duan, Hui Deng, Qun Xue, Haishan Jiang, Fei Xiao, Huan Yang, Ting Chang, Zhangyu Zou, Haifeng Li, Song Tan, Haibing Xiao, Hongyu Zhou, Hua Zhang, Qiang Meng, Wenyu Li, Wei Li, Junhong Guo, Yali Zhang, Zunbo Li, Jianglong Tu, Jianquan Shi, Wei Li, Michael Lee, Yu Chen, Xiaolu Tao, Shuai Zhao, Ping Li, Chongbo Zhao
IMPORTANCE: Myasthenia gravis (MG) is caused by autoantibodies that disrupt the neuromuscular junction. The neonatal fragment crystallizable receptor (FcRn) antagonists, efgartigimod and rozanolixizumab, reduce immunoglobulin G (IgG) level in the circulation and alleviate symptoms in patients with generalized MG. OBJECTIVE: To examine the efficacy and safety profile of batoclimab, a monoclonal IgG1 antibody, in patients with generalized MG. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter randomized clinical trial conducted from September 15, 2021, to June 29, 2022, at 27 centers in China...
March 4, 2024: JAMA Neurology
#32
JOURNAL ARTICLE
Yu Ni, Chen Liu, Liang Tan
No abstract text is available yet for this article.
March 4, 2024: JAMA Neurology
#33
JOURNAL ARTICLE
Aichun Cheng, Jing Xue, Anxin Wang, Qin Xu, Zhiyuan Feng, Jinxi Lin, Hao Li, Xia Meng, Jie Xu, Yongjun Wang
IMPORTANCE: Evidence on the bleeding risk associated with low-density lipoprotein cholesterol (LDL-C) levels in patients receiving dual antiplatelet therapy (DAPT) remains sparse. OBJECTIVE: To investigate the association of LDL-C levels with bleeding risk in patients with minor ischemic stroke (MIS) or high-risk transient ischemic attack (HRTIA) receiving DAPT. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was an analysis of pooled data from 2 randomized, double-blind, placebo-controlled clinical trials in China of patients with MIS or HRTIA who were receiving DAPT: the CHANCE (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) trial enrolled patients at 114 sites from October 2009 to July 2012, and the CHANCE-2 enrolled patients at 202 centers from September 2019 to March 2021...
March 4, 2024: JAMA Neurology
#34
JOURNAL ARTICLE
Hao Chen, Haiyan Tong, Yunan Xu
No abstract text is available yet for this article.
March 4, 2024: JAMA Neurology
#35
JOURNAL ARTICLE
Daniela Renedo, Julian N Acosta, Audrey C Leasure, Richa Sharma, Harlan M Krumholz, Adam de Havenon, Fares Alahdab, Aleksandr Y Aravkin, Zahra Aryan, Till Winfried Bärnighausen, Sanjay Basu, Katrin Burkart, Kaleb Coberly, Michael H Criqui, Xiaochen Dai, Rupak Desai, Samath Dhamminda Dharmaratne, Rajkumar Doshi, Islam Y Elgendy, Valery L Feigin, Irina Filip, Mohamed M Gad, Sherief Ghozy, Nima Hafezi-Nejad, Rizwan Kalani, Ibraheem M Karaye, Adnan Kisa, Vijay Krishnamoorthy, Warren Lo, Tomislav Mestrovic, Ted R Miller, Awoke Misganaw, Ali H Mokdad, Christopher J L Murray, Zuhair S Natto, Amir Radfar, Pradhum Ram, Gregory A Roth, Allen Seylani, Nilay S Shah, Purva Sharma, Aziz Sheikh, Jasvinder A Singh, Suhang Song, Houman Sotoudeh, Dominique Vervoort, Cong Wang, Hong Xiao, Suowen Xu, Ramin Zand, Guido J Falcone, Kevin N Sheth
IMPORTANCE: Stroke is a leading cause of death and disability in the US. Accurate and updated measures of stroke burden are needed to guide public health policies. OBJECTIVE: To present burden estimates of ischemic and hemorrhagic stroke in the US in 2019 and describe trends from 1990 to 2019 by age, sex, and geographic location. DESIGN, SETTING, AND PARTICIPANTS: An in-depth cross-sectional analysis of the 2019 Global Burden of Disease study was conducted...
March 4, 2024: JAMA Neurology
#36
JOURNAL ARTICLE
David Fischer, Brian L Edlow
IMPORTANCE: Among the most impactful neurologic assessments is that of neuroprognostication, defined here as the prediction of neurologic recovery from disorders of consciousness caused by severe, acute brain injury. Across a range of brain injury etiologies, these determinations often dictate whether life-sustaining treatment is continued or withdrawn; thus, they have major implications for morbidity, mortality, and health care costs. Neuroprognostication relies on a diverse array of tests, including behavioral, radiologic, physiological, and serologic markers, that evaluate the brain's functional and structural integrity...
March 4, 2024: JAMA Neurology
#37
JOURNAL ARTICLE
Elle Maureen Newcome
No abstract text is available yet for this article.
February 26, 2024: JAMA Neurology
#38
JOURNAL ARTICLE
Frank Porreca, David W Dodick
No abstract text is available yet for this article.
February 26, 2024: JAMA Neurology
#39
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 26, 2024: JAMA Neurology
#40
JOURNAL ARTICLE
Sae-Yeon Won, Silvia Hernández-Durán, Bedjan Behmanesh, Joshua D Bernstock, Marcus Czabanka, Nazife Dinc, Daniel Dubinski, Thomas M Freiman, Albrecht Günther, Kara Hellmuth, Eva Herrmann, Juergen Konczalla, Ilko Maier, Ruzanna Melkonian, Dorothee Mielke, Paul Naser, Veit Rohde, Christian Senft, Alexander Storch, Andreas Unterberg, Johannes Walter, Uwe Walter, Matthias Wittstock, Jan Hendrik Schaefer, Florian Gessler
IMPORTANCE: According to the current American Heart Association/American Stroke Association guidelines, decompressive surgery is indicated in patients with cerebellar infarcts that demonstrate severe cerebellar swelling. However, there is no universal definition of swelling and/or infarct volume(s) available to support a decision for surgery. OBJECTIVE: To evaluate functional outcomes in surgically compared with conservatively managed patients with cerebellar infarcts...
February 26, 2024: JAMA Neurology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
